Botanix Pharmaceuticals Ltd (ASX: BOT) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Botanix Pharmaceuticals Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$72.99 million
P/E Ratio
N/A
Dividend Yield
N/A
Shares Outstanding
973.14 million
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
-39.20%
Earnings Yield
N/A
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Botanix Pharmaceuticals Ltd (ASX: BOT)
Latest News
Share Market News
Which ASX cannabis shares should you buy in November?
Share Market News
The cannabis collapse: ASX marijuana shares going cheap
Share Fallers
Why Botanix, Elixinol Global, Pro Medicus, & Tinybeans shares tumbled lower
Share Fallers
Why the Botanix share price could crash lower on Wednesday
Share Market News
Should you still be invested in ASX marijuana shares?
Share Market News
Why the Botanix share price is sagging today
Share Gainers
Why Bellamy’s, Botanix, Objective Corp, & St Barbara shares charged higher today
Share Gainers
Why cannabis company Botanix rocketed higher today
BOT ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Botanix Pharmaceuticals Ltd
Botanix Pharmaceuticals Ltd is a clinical stage cannabinoid therapeutics company. The company focus is the development of safe and effective topical treatments for serious skin conditions. It has an exclusive license to use a proprietary drug delivery system - Permetrex for direct skin delivery of active pharmaceuticals in all skin diseases. The company's product pipeline includes BTX1503 - Moderate to Severe Acne, BTX1308 - Plaque Psoriasis, BTX1204 - Atopic Dermatitis, andBTX 1701 - Mild Acne.
BOT Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 30 Jul 2021 | $0.08 | $0.00 | 0.00% | 351,869 | $0.08 | $0.08 | $0.08 |
| 29 Jul 2021 | $0.08 | $0.00 | 0.00% | 1,042,970 | $0.08 | $0.08 | $0.08 |
| 28 Jul 2021 | $0.08 | $0.00 | 0.00% | 553,790 | $0.08 | $0.08 | $0.08 |
| 27 Jul 2021 | $0.08 | $0.00 | 0.00% | 1,522,464 | $0.08 | $0.08 | $0.08 |
| 26 Jul 2021 | $0.08 | $0.00 | 0.00% | 1,675,719 | $0.08 | $0.08 | $0.08 |
| 23 Jul 2021 | $0.08 | $0.00 | 0.00% | 868,514 | $0.08 | $0.08 | $0.08 |
| 22 Jul 2021 | $0.08 | $0.00 | 0.00% | 489,736 | $0.08 | $0.08 | $0.08 |
| 21 Jul 2021 | $0.08 | $0.00 | 0.00% | 580,162 | $0.08 | $0.08 | $0.08 |
| 20 Jul 2021 | $0.08 | $0.00 | 0.00% | 668,144 | $0.08 | $0.08 | $0.08 |
| 19 Jul 2021 | $0.08 | $0.00 | 0.00% | 1,612,225 | $0.08 | $0.08 | $0.08 |
| 16 Jul 2021 | $0.08 | $0.00 | 0.00% | 937,303 | $0.08 | $0.08 | $0.08 |
| 15 Jul 2021 | $0.08 | $0.00 | 0.00% | 194,542 | $0.08 | $0.08 | $0.08 |
| 14 Jul 2021 | $0.08 | $0.00 | 0.00% | 510,559 | $0.08 | $0.08 | $0.08 |
| 13 Jul 2021 | $0.08 | $0.00 | 0.00% | 1,061,512 | $0.09 | $0.09 | $0.08 |
| 12 Jul 2021 | $0.09 | $0.00 | 0.00% | 990,839 | $0.09 | $0.09 | $0.08 |
| 09 Jul 2021 | $0.08 | $0.00 | 0.00% | 633,611 | $0.08 | $0.09 | $0.08 |
| 08 Jul 2021 | $0.09 | $0.00 | 0.00% | 1,354,300 | $0.09 | $0.09 | $0.09 |
| 07 Jul 2021 | $0.09 | $0.00 | 0.00% | 1,613,389 | $0.09 | $0.09 | $0.09 |
| 06 Jul 2021 | $0.09 | $0.00 | 0.00% | 663,169 | $0.09 | $0.09 | $0.09 |
| 05 Jul 2021 | $0.09 | $-0.01 | -10.75% | 1,637,538 | $0.09 | $0.09 | $0.09 |
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Matthew (Matt) Callahan | Executive Director | Feb 2020 |
Mr Callahan is an experienced life sciences executive based in Philadelphia. He is a founder of Botanix and coinventor of many of the Company's Permetrex enabled products. Matt was the founding CEO of Churchill Pharmaceuticals and developed Yonsa through FDA approval and subsequent sale to Sun Pharmaceuticals. He was also founding CEO of drug delivery company iCeutica Inc which developed 4 FDA approved products and was sold to Iroko Pharmaceuticals. He has more than 25 years legal, IP and investment management experience.
|
| Dr Stewart James Washer | Non-Executive Director | Feb 2019 |
Dr Washer has CEO and Board experience in medical biotech and cannabinoid companies. He is currently the Executive Chairman of Emerald Clinics, medical cannabis patient data collection and clinics.
|
| Dr H. William Bosch | Executive Director | Jul 2016 |
Dr Bosch is a seasoned Pharmaceuticals executive with more than 25 years of experience in the industry, focusing on applications of drug delivery technology to Pharmaceuticals product development. Dr Bosch also works with iCeutica Inc. and is a co-inventor of the SoluMatrix technology and has been instrumental in the development and scale up of the platform and the development of the three FDA approved products that use that drug delivery technology.
|
| Mr Vince Ippolito | PresidentExecutive ChairmanExecutive Director | May 2019 |
Mr Ippolito has more than 30 years of experience in the pharmaceuticals industry, including more over 20 years' experience in dermatology. He most recently served as President and Chief Operating Officer of Dermavant Sciences, a specialty biopharmaceutical company that is commercialising products which treat inflammatory skin diseases and medical dermatologic conditions. Mr Ippolito also sits on the Board of Suneva Medical, a privately held regenerative aesthetics company.
|
| Mr Simon Lee Robertson | Company Secretary | Feb 2017 |
-
|
| Simon Lee Robertson | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Shenasaby Investments Pty Ltd | 70,738,307 | 7.27% |
| Caperi Pty Ltd | 59,573,784 | 6.12% |
| Dr Henry William Bosch | 16,000,000 | 1.64% |
| Yarraandoo Pty Ltd | 10,000,000 | 1.03% |
| Sweet As Developments Pty Lt | 9,815,455 | 1.01% |
| Citicorp Nominees Pty Limited | 9,307,982 | 0.96% |
| Mr Ka Kian Lim | 9,263,000 | 0.95% |
| Zenith Pacific Limited | 9,000,000 | 0.93% |
| Zanya Nminees Pty Ld | 8,584,545 | 0.88% |
| Jp Morgan Nominees Australia Pty Limited | 7,756,446 | 0.80% |
| Mr Ancuan Lim | 7,672,000 | 0.79% |
| HSBC Custody Nominees (Australia) Limited | 7,315,893 | 0.75% |
| T T Nicholls Pty Ltd | 7,000,000 | 0.72% |
| Mr Michael William Gaule | 6,384,494 | 0.66% |
| Splendid Stuff Pty Ltd | 6,242,156 | 0.64% |
| J & N Weston Investments Pty Ltd | 5,650,000 | 0.58% |
| Mr Stephane Nicolas Fayd'Herbe | 5,625,000 | 0.58% |
| BNP Paribas Nominees Pty Ltd | 5,435,688 | 0.56% |
| Mr Brendan Paul Cooper | 5,373,413 | 0.55% |
| Argonaut Investments Pty Ltd | 5,000,000 | 0.51% |